Shares in US biotech Alnylam have soared after a late-stage study of its RNA interference drug patisaran met its primary endpoint. The results are a landmark for Alnylam which has stuck doggedly ...

--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration’s ...

Dicerna Pharma has enticed another big pharma to partner its RNA interference platform, attracting a $200 million upfront deal with Roche for a drug to treat hepatitis B virus infections.

As RNA-based drugs can block the biogenesis of specific proteins without altering the genome, they may be better suited to inhibiting their production, improving therapeutic efficacy. Another key ...

The identification of such interactions can yield novel drug targets and guide further investigation of cancer-specific vulnerabilities. RNAi as a tool for functional genomics & identification of ...

Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering RNA (siRNA) drug ...